Our clinical data further supported these observations, revealing that advanced HCC patients with lower LSD1 levels tended to exhibit higher CD74 expression and prolonged durable control following anti‐PD1 therapy. This evidence concerns the gene KDM1A and hepatocellular carcinoma.